{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:41:20Z","timestamp":1773207680639,"version":"3.50.1"},"reference-count":99,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Proyectos Santander\/Complutense","award":["PR87\/19-22646"],"award-info":[{"award-number":["PR87\/19-22646"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Visceral leishmaniasis (VL), a vector-borne parasitic disease caused by Leishmania donovani and L. infantum (Kinetoplastida), affects humans and dogs, being fatal unless treated. Miltefosine (MIL) is the only oral medication for VL and is considered a first choice drug when resistance to antimonials is present. Comorbidity and comedication are common in many affected patients but the relationship between microbiome composition, drugs administered and their pharmacology is still unknown. To explore the effect of clindamycin on the intestinal microbiome and the availability and distribution of MIL in target organs, Syrian hamsters (120\u2013140 g) were inoculated with L. infantum (108 promastigotes\/animal). Infection was maintained for 16 weeks, and the animals were treated with MIL (7 days, 5 mg\/kg\/day), clindamycin (1 mg\/kg, single dose) + MIL (7 days, 5 mg\/kg\/day) or kept untreated. Infection was monitored by ELISA and fecal samples (16 wpi, 18 wpi, end point) were analyzed to determine the 16S metagenomic composition (OTUs) of the microbiome. MIL levels were determined by LC-MS\/MS in plasma (24 h after the last treatment; end point) and target organs (spleen, liver) (end point). MIL did not significantly affect the composition of intestinal microbiome, but clindamycin provoked a transient albeit significant modification of the relative abundance of 45% of the genera, including Ruminococcaceae UCG-014, Ruminococcus 2; Bacteroides and (Eubacterium) ruminantium group, besides its effect on less abundant phyla and families. Intestinal dysbiosis in the antibiotic-treated animals was associated with significantly lower levels of MIL in plasma, though not in target organs at the end of the experiment. No clear relationship between microbiome composition (OTUs) and pharmacological parameters was found.<\/jats:p>","DOI":"10.3390\/antibiotics12020362","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T02:56:13Z","timestamp":1675997773000},"page":"362","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Clindamycin on Intestinal Microbiome and Miltefosine Pharmacology in Hamsters Infected with Leishmania infantum"],"prefix":"10.3390","volume":"12","author":[{"given":"Ana Isabel","family":"Ol\u00edas-Molero","sequence":"first","affiliation":[{"name":"ICPVet, Department of Animal Health, School of Veterinary Sciences, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4416-9118","authenticated-orcid":false,"given":"Pedro","family":"Bot\u00edas","sequence":"additional","affiliation":[{"name":"Genomics Unit, Research Assistance Center of Biological Techniques, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Cuquerella","sequence":"additional","affiliation":[{"name":"ICPVet, Department of Animal Health, School of Veterinary Sciences, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-1273","authenticated-orcid":false,"given":"Jes\u00fas","family":"Garc\u00eda-Cantalejo","sequence":"additional","affiliation":[{"name":"Genomics Unit, Research Assistance Center of Biological Techniques, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0566-2367","authenticated-orcid":false,"given":"Emilia","family":"Barcia","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Food Technology, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"},{"name":"Institute of Industrial Pharmacy UCM, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Torrado","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Food Technology, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"},{"name":"Institute of Industrial Pharmacy UCM, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Torrado","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Food Technology, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"},{"name":"Institute of Industrial Pharmacy UCM, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1491-8627","authenticated-orcid":false,"given":"Jos\u00e9 Mar\u00eda","family":"Alunda","sequence":"additional","affiliation":[{"name":"ICPVet, Department of Animal Health, School of Veterinary Sciences, Complutense University of Madrid, 28040 Madrid, Spain"},{"name":"Institute of Industrial Pharmacy UCM, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"ref_1","unstructured":"Expert Committee on the Control of the Leishmaniases & World Health Organization (2022, October 22). Control of the Leishmaniases: Report of a Meeting of the WHO Expert Commitee on the Control of Leishmaniases, Geneva, Switzerland, 22\u201326 March 2010. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/44412."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Alvar, J., V\u00e9lez, I.D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., den Boer, M., and WHO Leishmaniasis Control Team (2012). Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035671"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jinf.2014.07.016","article-title":"Leishmaniasis","volume":"69","author":"Pace","year":"2014","journal-title":"J. Infect."},{"key":"ref_4","unstructured":"WHO (2023, January 29). Leishmaniasis. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13071-016-1551-0","article-title":"First report of transmission of canine leishmaniosis through bite wounds from a naturally infected dog in Germany","volume":"9","author":"Naucke","year":"2016","journal-title":"Parasit. Vectors"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4081\/gh.2017.503","article-title":"Epidemiological aspects and spatial distribution of human and canine visceral leishmaniasis in an endemic area in northeastern Brazil","volume":"12","author":"Campos","year":"2017","journal-title":"Geospatial Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.35500\/jghs.2020.2.e3","article-title":"Visceral leishmaniasis: A global overview","volume":"2","author":"Wamai","year":"2020","journal-title":"J. Glob. Health Sci."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Morales-Yuste, M., Mart\u00edn-S\u00e1nchez, J., and Corpas-Lopez, V. (2022). Canine Leishmaniasis: Update on epidemiology, diagnosis, treatment, and prevention. Vet. Sci., 9.","DOI":"10.3390\/vetsci9080387"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"13325","DOI":"10.1038\/s41598-017-13822-1","article-title":"Modeling the climatic suitability of leishmaniasis vector species in Europe","volume":"7","author":"Koch","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kholoud, K., Denis, S., Lahouari, B., El Hidan, M.A., and Souad, B. (2018). Management of Leishmaniases in the era of climate change in Morocco. Int. J. Environ. Res. Public Health, 15.","DOI":"10.3390\/ijerph15071542"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"11820","DOI":"10.1038\/s41598-019-48350-7","article-title":"The changing distribution of Leishmania infantum Nicolle, 1908 and its Mediterranean sandfly vectors in the last 140 kys","volume":"9","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100159","DOI":"10.1016\/j.onehlt.2020.100159","article-title":"Integrating environmental, entomological, animal, and human data to model the Leishmania infantum transmission risk in a newly endemic area in Northern Italy","volume":"10","author":"Moirano","year":"2020","journal-title":"One Health"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1046\/j.1198-743x.2001.00262.x","article-title":"HIV-associated visceral leishmaniasis","volume":"7","author":"Pintado","year":"2001","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1473-3099(08)70043-4","article-title":"Leishmaniasis among organ transplant recipients","volume":"8","author":"Antinori","year":"2008","journal-title":"Lancet. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Monge-Maillo, B., Norman, F.F., Cruz, I., Alvar, J., and L\u00f3pez-V\u00e9lez, R. (2014). Visceral leishmaniasis and HIV coinfection in the Mediterranean region. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0003021"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/1469-0691.12556","article-title":"Leishmaniasis in immunosuppressed individuals","volume":"20","author":"Carrillo","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e12867","DOI":"10.1111\/ctr.12867","article-title":"Leishmaniasis in solid organ and hematopoietic stem cell transplant recipients","volume":"31","author":"Gajurel","year":"2017","journal-title":"Clin. Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Carrillo, E., Carrasco-Ant\u00f3n, N., L\u00f3pez-Medrano, F., Salto, E., Fern\u00e1ndez, L., San Mart\u00edn, J.V., Alvar, J., Aguado, J.M., and Moreno, J. (2015). Cytokine release assays as tests for exposure to Leishmania, and for confirming cure from leishmaniasis, in solid organ transplant recipients. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0004179"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/flgastro-2020-101659","article-title":"Donor acquired visceral leishmaniasis following liver transplantation","volume":"12","author":"Dhaliwal","year":"2021","journal-title":"Frontline Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Busutti, M., Deni, A., De Pascali, A.M., Ortalli, M., Attard, L., Granozzi, B., Fabbrizio, B., La Manna, G., Comai, G., and Varani, S. (2022). Updated diagnosis and graft involvement for visceral leishmaniasis in kidney transplant recipients: A case report and literature review. Infection, 1\u201312.","DOI":"10.1007\/s15010-022-01943-3"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/14787210.2018.1473763","article-title":"Current approaches to visceral leishmaniasis treatment in solid organ transplant recipients","volume":"16","author":"Clemente","year":"2018","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_22","first-page":"193","article-title":"Visceral leishmaniasis and HIV coinfection: Current perspectives","volume":"15","author":"Lindoso","year":"2018","journal-title":"HIV AIDS"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1473-3099(22)00461-3","article-title":"Guidelines for visceral leishmaniasis and HIV co-infection","volume":"22","author":"Burki","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_24","unstructured":"(2023, January 26). WHO. Available online: https:\/\/www.who.int\/news\/item\/08-06-2022-visceral-leishmaniasis-and-HIV-coinfection-WHO-publishes-new-guideline-with-region-specific-treatment-recommendations."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1763","DOI":"10.1016\/S2214-109X(21)00392-2","article-title":"Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: Reflections on an enhanced control strategy and a call for action","volume":"9","author":"Alvar","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/tmi.13382","article-title":"Commercially approved vaccines for canine leishmaniosis: A review of available data on their safety and efficacy","volume":"25","author":"Velez","year":"2020","journal-title":"Trop. Med. Int. Health"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/1381612023396258","article-title":"Chemotherapy of leishmaniasis","volume":"8","author":"Croft","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"J\u00e4ger, T., Koch, O., and Floh\u00e9, L. (2013). Trypanosomatid Diseases; Molecular Routes to Drug Discovery, Wiley-VCH.","DOI":"10.1002\/9783527670383"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1017\/S0031182016002523","article-title":"Chemotherapy of leishmaniasis: Present challenges","volume":"145","author":"Uliana","year":"2018","journal-title":"Parasitology"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ponte-Sucre, A., Gamarro, F., Dujardin, J.C., Barrett, M.P., L\u00f3pez-V\u00e9lez, R., Garc\u00eda-Hern\u00e1ndez, R., Pountain, A.W., Mwenechanya, R., and Papadopoulou, B. (2017). Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0006052"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40249-016-0112-2","article-title":"Current challenges in treatment options for visceral leishmaniasis in India: A public health perspective","volume":"5","author":"Singh","year":"2016","journal-title":"Infect. Dis. Poverty"},{"key":"ref_32","first-page":"1","article-title":"Could combination chemotherapy be more effective than monotherapy in the treatment of visceral leishmaniasis? A systematic review of preclinical evidence","volume":"9","author":"Bastos","year":"2022","journal-title":"Parasitology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1016925","DOI":"10.3389\/fbioe.2022.1016925","article-title":"Limitations of current chemotherapy and future of nanoformulation-based AmB delivery for visceral leishmaniasis\u2014An updated review","volume":"10","author":"Kumar","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Musa, A.M., Mbui, J., Mohammed, R., Olobo, J., Ritmeijer, K., Alcoba, G., Muthoni Ouattara, G., Egondi, T., Nakanwagi, P., and Omollo, T. (2022). Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in eastern Africa: A randomized, controlled, multicountry trial. Clin. Infect. Dis., ciac643.","DOI":"10.1093\/cid\/ciac643"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1515\/pac-2018-1102","article-title":"Current and promising novel drug candidates against visceral leishmaniasis","volume":"91","author":"Reguera","year":"2019","journal-title":"Pure Appl. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"eBioMedicine (2023). Leishmania: An urgent need for new treatments. eBioMedicine, 87, 104440.","DOI":"10.1016\/j.ebiom.2023.104440"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.trstmh.2006.02.010","article-title":"Development of miltefosine as an oral treatment for leishmaniasis","volume":"100","author":"Sinderman","year":"2006","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e01678-17","DOI":"10.1128\/AAC.01678-17","article-title":"In vitro activities of miltefosine and antibacterial agents from the macrolide, oxazolidinone, and pleuromutilin classes against Pythium insidiosum and Pythium aphanidermatum","volume":"62","author":"Loreto","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e01409-18","DOI":"10.1128\/AAC.01409-18","article-title":"Miltefosine reduces the cytolytic activity and virulence of Acinetobacter baumannii","volume":"63","author":"Fiester","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1128\/AAC.01428-06","article-title":"In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic Streptococci","volume":"51","author":"Llull","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","first-page":"733","article-title":"Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management","volume":"3","author":"Sundar","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1086\/318122","article-title":"Short-course of oral miltefosine for treatment of visceral leishmaniasis","volume":"31","author":"Sundar","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","first-page":"1398","article-title":"Miltefosine for visceral and cutaneous leishmaniasis: Drug characteristics and evidence-based treatment recommendations","volume":"60","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1517\/14656566.6.8.1381","article-title":"Miltefosine to treat leishmaniasis","volume":"6","author":"Berman","year":"2005","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4103\/0974-777X.62887","article-title":"Drug resistance in leishmaniasis","volume":"2","author":"Chakravarty","year":"2010","journal-title":"J. Glob. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/BF02535556","article-title":"Distribution and metabolism of hexadecylphosphocholine in mice","volume":"22","author":"Breiser","year":"1987","journal-title":"Lipids"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jchromb.2016.07.042","article-title":"Pharmacokinetic and bioavailability assessment of miltefosine in rats. Pharmacokinetic and bioavailability assessment of miltefosine in rats using high performance liquid chromatography tandem mass spectrometry","volume":"1031","author":"Valicherla","year":"2016","journal-title":"J. Chromatogr. B"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4155\/bio.16.7","article-title":"LC-coupled ESI MS for quantification of miltefosine in human and hamster plasma","volume":"8","author":"Jaiswal","year":"2016","journal-title":"Bioanalysis"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/infdis\/jiu039","article-title":"Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure","volume":"210","author":"Dorlo","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Wasunna, M., Njenga, S., Balasegaram, M., Alexander, N., Omollo, R., Edwards, T., Dorlo, T.P., Musa, B., Ali, M.H., and Elamin, M.Y. (2016). Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: Phase II randomized trial. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004880"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"590888","DOI":"10.3389\/fcimb.2020.590888","article-title":"Genetics, transcriptomics and meta-taxonomics in visceral leishmaniasis","volume":"5","author":"Blackwell","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lappan, R., Classon, C., Kumar, S., Singh, O.P., de Almeida, R.V., Chakravarty, J., Kumari, P., Kansal, S., Sundar, S., and Blackwell, J.M. (2019). Meta-taxonomic analysis of prokaryotic and eukaryotic gut flora in stool samples from visceral leishmaniasis cases and endemic controls in Bihar State India. PLoS Negl. Trop. Dis., 13.","DOI":"10.1101\/630624"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"23181","DOI":"10.1038\/s41598-021-02388-8","article-title":"Distinct microbiome profiles and biofilms in Leishmania donovani-driven cutaneous leishmaniasis wounds","volume":"11","author":"Campbell","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e200377","DOI":"10.1590\/0074-02760200377","article-title":"Investigating associations between intestinal alterations and parasite load according to Bifidobacterium spp. and Lactobacillus spp. abundance in the gut microbiota of hamsters infected by Leishmania infantum","volume":"115","author":"Corvo","year":"2020","journal-title":"Mem. Inst. Oswaldo Cruz Rio de Janeiro"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s13071-022-05576-1","article-title":"Leishmania infantum infection does not affect the main composition of the intestinal microbiome of the Syrian hamster","volume":"15","author":"Cuquerella","year":"2022","journal-title":"Parasit. Vectors"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cmi.2017.09.017","article-title":"Impact of antibiotics on the intestinal microbiota needs to be re-defined to optimize antibiotic usage","volume":"24","author":"Burdet","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1111\/bph.14366","article-title":"Drug-gut microbiota interactions: Implications for neuropharmacology","volume":"175","author":"Walsh","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13071-019-3312-3","article-title":"Comorbid infections induce progression of visceral leishmaniasis","volume":"23","author":"Toepp","year":"2019","journal-title":"Parasit. Vectors"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Khayeka-Wandabwa, C., Anjili, C.O., Nyambati, V.C., Kutima, L.H., Choge, J.K., Karani, L.K., and Kemei, W.K. (2020). Leishmaniases and schistosomiasis comorbidity potential in Kenya: The need for follow up studies. Preprints, 2020100268.","DOI":"10.20944\/preprints202010.0268.v1"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jiph.2019.10.003","article-title":"Risk factors for in-hospital mortality from visceral leishmaniasis: A case-control study","volume":"13","author":"Werneck","year":"2020","journal-title":"J. Infect. Public Health"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"653999","DOI":"10.3389\/fvets.2021.653999","article-title":"Trends in the epidemiology of Leishmaniasis in the city of Barcelona (1996\u20132019)","volume":"8","author":"Palma","year":"2021","journal-title":"Front. Vet. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jinf.2019.10.008","article-title":"The effect of antibiotics on the composition of the intestinal microbiota-a systematic review","volume":"79","author":"Zimmermann","year":"2019","journal-title":"J. Infect."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"572912","DOI":"10.3389\/fcimb.2020.572912","article-title":"Antibiotics as major disruptors of gut microbiota","volume":"10","author":"Ramirez","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijpddr.2013.11.002","article-title":"Untargeted metabolomic analysis of miltefosine action in Leishmania infantum reveals changes to the internal lipid metabolism","volume":"4","author":"Vincent","year":"2013","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/bph.15368","article-title":"The anti-parasitic drug miltefosine suppresses activation of human eosinophils and ameliorates allergic inflammation in mice","volume":"178","author":"Knuplez","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0163-7827(99)00004-1","article-title":"Mechanisms of action of phospholipid analogs as anticancer compounds","volume":"38","author":"Wieder","year":"1999","journal-title":"Prog. Lipid. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1128\/AAC.01123-06","article-title":"Miltefosine affects lipid metabolism in Leishmania donovani promastigotes","volume":"51","author":"Rakotomanga","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"647870","DOI":"10.3389\/fcimb.2021.647870","article-title":"De novo synthesis of phosphatidylcholine is essential for the promastigote but not amastigote stage in Leishmania major","volume":"11","author":"Moitra","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bbalip.2012.08.009","article-title":"Phosphatidylcholine biosynthesis and function in bacteria","volume":"1831","author":"Geiger","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00436-009-1404-2","article-title":"Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis","volume":"105","author":"Woerly","year":"2009","journal-title":"Parasitol. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"577395","DOI":"10.3389\/fvets.2020.577395","article-title":"Comparison of two dosing regimens of miltefosine, both in combination with allopurinol, on clinical and parasitological findings of dogs with leishmaniosis: A pilot study","volume":"7","author":"Iarussi","year":"2020","journal-title":"Front. Vet. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12275-018-8024-4","article-title":"The Ruminococci: Key symbionts of the gut ecosystem","volume":"56","author":"Suen","year":"2018","journal-title":"J. Microbiol."},{"key":"ref_74","first-page":"22","article-title":"Current indications for the use of clindamycin: A critical review","volume":"9","author":"Smieja","year":"1998","journal-title":"Can. J. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0065-2164(04)56004-5","article-title":"Lincosamides: Chemical structure, biosynthesis, mechanism of action, resistance, and applications","volume":"56","author":"Spizek","year":"2004","journal-title":"Adv. Appl. Microbiol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Hertz, F.B., Budding, A.E., Van der Lugt-Degen, M., Savelkoul, P.H., L\u00f8bner-Olesen, A., and Frimodt-M\u00f8ller, N. (2020). Effects of antibiotics on the intestinal microbiota of mice. Antibiotics, 9.","DOI":"10.3390\/antibiotics9040191"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1128\/IAI.00558-09","article-title":"Antibiotic treatment of clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts","volume":"77","author":"Lawley","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/IAI.05496-11","article-title":"Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis","volume":"80","author":"Buffie","year":"2012","journal-title":"Infect. Immun."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Peterfreund, G.L., Vandivier, L.E., Sinha, R., Marozsan, A.J., Olson, W.C., Zhu, J., and Bushman, F.D. (2012). Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficile. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046966"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1017\/S0022029913000216","article-title":"Protective effect of bifidobacteria in an experimental model of Clostridium difficile associated colitis","volume":"80","author":"Trejo","year":"2013","journal-title":"J. Dairy Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bcp.2016.09.007","article-title":"Antibiotic use and microbiome function","volume":"134","author":"Ferrer","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e00925-18","DOI":"10.1128\/AAC.00925-18","article-title":"Antibiotic-induced dysbiosis predicts mortality in an animal model of Clostridium difficile infection","volume":"62","author":"Burdet","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13568-021-01274-w","article-title":"The varying effects of antibiotics on gut microbiota","volume":"11","author":"Yang","year":"2021","journal-title":"AMB Express"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e01960-21","DOI":"10.1128\/spectrum.01960-21","article-title":"Microbiome resilience despite a profound loss of minority microbiota following clindamycin challenge in humanized gnotobiotic mice","volume":"10","author":"Liu","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jgar.2017.11.001","article-title":"In vitro effect of clindamycin against Bacteroides and Parabacteroides isolates in Poland","volume":"13","author":"Kierzkowska","year":"2018","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jff.2019.05.032","article-title":"Dietary supplementation of soybean-derived sterols regulates cholesterol metabolism and intestinal microbiota in hamsters","volume":"59","author":"Li","year":"2019","journal-title":"J. Funct. Foods"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00018-017-2693-8","article-title":"Mouse models for human intestinal microbiota research: A critical evaluation","volume":"75","author":"Hugenholtz","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.3389\/fmicb.2018.01598","article-title":"Microbiome composition in both wild-type and disease model mice is heavily influenced by mouse facility","volume":"9","author":"Parker","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejps.2018.06.002","article-title":"Pharmacokinetics and disposition of miltefosine in healthy mice and hamsters experimentally infected with Leishmania infantum","volume":"121","author":"Escribano","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40262-017-0570-0","article-title":"Clinical pharmacokinetics of systemically administered antileishmanial drugs","volume":"57","author":"Kip","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1177\/0192623309344088","article-title":"Administration of miltefosine and meglumine antimoniate in healthy dogs: Clinicopathological evaluation of the impact on the kidneys","volume":"37","author":"Bianciardi","year":"2009","journal-title":"Toxicol. Pathol."},{"key":"ref_92","first-page":"555798","article-title":"Phospholipases in bacterial virulence and pathogenesis","volume":"10","author":"Bandana","year":"2018","journal-title":"Adv. Biotechnol. Microbiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"100547","DOI":"10.1016\/j.mgene.2019.100547","article-title":"An insight into bacterial phospholipase C classification and their translocation through Tat and Sec pathways: A data mining study","volume":"20","author":"Sinha","year":"2019","journal-title":"Meta Gene"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/19490976.2015.1062959","article-title":"Dynamic changes of the luminal and mucosa-associated gut microbiota during and after antibiotic therapy with paromomycin","volume":"6","author":"Heinsen","year":"2015","journal-title":"Gut Microbes"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41385-019-0238-1","article-title":"Antibiotic-induced microbiome perturbations are associated with significant alterations to colonic mucosal immunity in rhesus macaques","volume":"13","author":"Manuzak","year":"2020","journal-title":"Mucosal Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1080\/21505594.2019.1649587","article-title":"Efficient infection of hamster with Leishmania donovani by retro-orbital inoculation","volume":"10","author":"Grau","year":"2019","journal-title":"Virulence"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jchromb.2008.02.005","article-title":"Development and validation of a quantitative assay for the measurement of MIL in human plasma by liquid chromatography-tandem mass spectrometry","volume":"865","author":"Dorlo","year":"2008","journal-title":"J. Chromatogr. B"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"D590","DOI":"10.1093\/nar\/gks1219","article-title":"The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools","volume":"41","author":"Quast","year":"2013","journal-title":"Nucl. Acids Res."},{"key":"ref_99","unstructured":"(2022, November 25). Available online: https:\/\/www.ncbi.nlm.nih.gov\/bioproject\/PRJNA843999."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/2\/362\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:28:57Z","timestamp":1760120937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/2\/362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":99,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["antibiotics12020362"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12020362","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]}}}